Gilead Sciences, Inc. (GILD.MX)
| Previous close | 1,277.00 |
| Open | 0.00 |
| Bid | 1,070.11 x 500000 |
| Ask | 1,198.97 x 300000 |
| Day's range | 1,277.00 - 1,277.00 |
| 52-week range | 1,046.71 - 1,486.00 |
| Volume | |
| Avg. volume | 254 |
| Market cap | 1.591T |
| Beta (5Y monthly) | 0.20 |
| PE ratio (TTM) | 196.16 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 56.46 (4.42%) |
| Ex-dividend date | 14 June 2024 |
| 1y target est | N/A |
- Business Wire
Gilead’s Twice-Yearly Lenacapavir Demonstrated 100% Efficacy and Superiority to Daily Truvada® for HIV Prevention
FOSTER CITY, Calif., June 20, 2024--Gilead Sciences, Inc. (Nasdaq: GILD) today announced topline results from an interim analysis of its pivotal, Phase 3 PURPOSE 1 trial indicating that the company’s twice-yearly injectable HIV-1 capsid inhibitor, lenacapavir, demonstrated 100% efficacy for the investigational use of HIV prevention in cisgender women.
- Business Wire
New Kite Clinical Research and Real-World Evidence for Yescarta® Demonstrate Benefit From Earlier Lines of Treatment
SANTA MONICA, Calif., June 14, 2024--Kite, a Gilead Company (Nasdaq: GILD), today announced results from three new analyses for Yescarta® (axicabtagene ciloleucel) in relapsed/refractory (R/R) large B-cell lymphoma (LBCL), including both new clinical research and real-world evidence highlighting manufacturing and product characteristics of Yescarta, and outpatient administration of both Yescarta and Tecartus® (brexucabtagene autoleucel) at the 2024 European Hematology Association (EHA) Annual Co
- Business Wire
Gilead Announces New England Journal of Medicine Publication of Data that Demonstrate Bulevirtide with PegIFN Achieved Post-Treatment Undetectable HDV RNA
FOSTER CITY, Calif., June 06, 2024--Gilead Sciences, Inc. (Nasdaq: GILD) today announced data from the Phase 2b MYR204 open-label study assessing the efficacy and safety of the first-in-class entry inhibitor bulevirtide as monotherapy and in combination with pegylated interferon alfa-2a (PegIFN), in adults living with compensated chronic hepatitis delta virus (HDV) infection. Published in the New England Journal of Medicine (NEJM), the data demonstrate that the investigational combination of bul
